Nutex Health (NASDAQ:NUTX) CFO Buys $102,532.50 in Stock

Nutex Health Inc. (NASDAQ:NUTX) CFO Jon Christian Bates bought 750 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was purchased at an average price of $136.71 per share, with a total value of $102,532.50. Following the completion of the transaction, the chief financial officer directly owned 5,638 shares of the company’s stock, valued at approximately $770,770.98. The trade was a 15.34% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Nutex Health Trading Up 4.0%

Shares of NASDAQ:NUTX traded up $4.48 during midday trading on Friday, hitting $117.28. 140,535 shares of the stock were exchanged, compared to its average volume of 150,022. The business’s 50-day moving average price is $112.55 and its 200 day moving average price is $113.50. Nutex Health Inc. has a 12 month low of $28.12 and a 12 month high of $184.27. The company has a debt-to-equity ratio of 1.02, a quick ratio of 2.26 and a current ratio of 2.27. The stock has a market capitalization of $829.40 million, a price-to-earnings ratio of 9.86 and a beta of -0.23.

Nutex Health (NASDAQ:NUTX) last issued its quarterly earnings data on Tuesday, November 18th. The company reported $7.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.43) by $13.19. Nutex Health had a net margin of 10.76% and a return on equity of 42.08%. The business had revenue of $243.99 million during the quarter, compared to analyst estimates of $221.93 million.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NUTX shares. Maxim Group set a $205.00 price target on shares of Nutex Health and gave the stock a “buy” rating in a report on Tuesday, August 26th. Weiss Ratings raised Nutex Health from a “sell (d)” rating to a “hold (c)” rating in a research report on Tuesday. Finally, Wall Street Zen lowered Nutex Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 18th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Nutex Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.50.

Institutional Investors Weigh In On Nutex Health

Several institutional investors and hedge funds have recently made changes to their positions in NUTX. State of Alaska Department of Revenue acquired a new position in Nutex Health in the third quarter valued at approximately $30,000. BNP Paribas Financial Markets grew its holdings in Nutex Health by 966.7% in the second quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after purchasing an additional 290 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in Nutex Health in the second quarter worth $44,000. Bank of America Corp DE boosted its position in shares of Nutex Health by 6,590.3% during the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company’s stock worth $66,000 after purchasing an additional 2,043 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Nutex Health in the 2nd quarter valued at about $97,000. Institutional investors own 5.32% of the company’s stock.

Nutex Health Company Profile

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.